409 related articles for article (PubMed ID: 7585539)
21. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
Huang X; Wong MK; Yi H; Watkins S; Laird AD; Wolf SF; Gorelik E
Cancer Res; 2002 Oct; 62(20):5727-35. PubMed ID: 12384531
[TBL] [Abstract][Full Text] [Related]
22. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
[TBL] [Abstract][Full Text] [Related]
23. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct.
Matulonis U; Dosiou C; Freeman G; Lamont C; Mauch P; Nadler LM; Griffin JD
J Immunol; 1996 Feb; 156(3):1126-31. PubMed ID: 8557988
[TBL] [Abstract][Full Text] [Related]
24. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.
Moro M; Gasparri AM; Pagano S; Bellone M; Tornaghi P; Veglia F; Corti A; Casorati G; Dellabona P
Cancer Res; 1999 Jun; 59(11):2650-6. PubMed ID: 10363988
[TBL] [Abstract][Full Text] [Related]
25. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
[TBL] [Abstract][Full Text] [Related]
27. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
Cayeux S; Beck C; Aicher A; Dörken B; Blankenstein T
Eur J Immunol; 1995 Aug; 25(8):2325-31. PubMed ID: 7545119
[TBL] [Abstract][Full Text] [Related]
28. Interferon-alpha and interleukin-12 gene therapy of cancer: interferon-alpha induces tumor-specific immune responses while interleukin-12 stimulates non-specific killing.
Eguchi J; Hiroishi K; Ishii S; Mitamura K
Cancer Immunol Immunother; 2003 Jun; 52(6):378-86. PubMed ID: 12739068
[TBL] [Abstract][Full Text] [Related]
29. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
30. Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
Liu A; Hu P; Khawli LA; Epstein AL
Clin Cancer Res; 2005 Dec; 11(23):8492-502. PubMed ID: 16322313
[TBL] [Abstract][Full Text] [Related]
31. IFN-gamma-independent synergistic effects of IL-12 and IL-15 induce anti-tumor immune responses in syngeneic mice.
Comes A; Di Carlo E; Musiani P; Rosso O; Meazza R; Chiodoni C; Colombo MP; Ferrini S
Eur J Immunol; 2002 Jul; 32(7):1914-23. PubMed ID: 12115611
[TBL] [Abstract][Full Text] [Related]
32. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model.
Emtage PC; Wan Y; Bramson JL; Graham FL; Gauldie J
J Immunol; 1998 Mar; 160(5):2531-8. PubMed ID: 9498799
[TBL] [Abstract][Full Text] [Related]
33. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules.
Baskar S; Clements VK; Glimcher LH; Nabavi N; Ostrand-Rosenberg S
J Immunol; 1996 May; 156(10):3821-7. PubMed ID: 8621919
[TBL] [Abstract][Full Text] [Related]
34. Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.
Gajewski TF; Renauld JC; Van Pel A; Boon T
J Immunol; 1995 Jun; 154(11):5637-48. PubMed ID: 7538528
[TBL] [Abstract][Full Text] [Related]
35. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
36. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
[TBL] [Abstract][Full Text] [Related]
37. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
Bian Y; Hiraoka S; Tomura M; Zhou XY; Yashiro-Ohtani Y; Mori Y; Shimizu J; Ono S; Dunussi-Joannopoulos K; Wolf S; Fujiwara H
Int Immunol; 2005 Jan; 17(1):73-83. PubMed ID: 15569772
[TBL] [Abstract][Full Text] [Related]
38. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.
Zitvogel L; Robbins PD; Storkus WJ; Clarke MR; Maeurer MJ; Campbell RL; Davis CG; Tahara H; Schreiber RD; Lotze MT
Eur J Immunol; 1996 Jun; 26(6):1335-41. PubMed ID: 8647214
[TBL] [Abstract][Full Text] [Related]
40. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]